Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CorMedix Inc (CRMD : NSDQ)
 
 • Company Description   
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog

Number of Employees: 30

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.27 Daily Weekly Monthly
20 Day Moving Average: 368,216 shares
Shares Outstanding: 39.12 (millions)
Market Capitalization: $127.93 (millions)
Beta: 2.39
52 Week High: $8.38
52 Week Low: $2.87
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -34.07% -28.03%
12 Week -18.86% -12.31%
Year To Date -28.13% -14.87%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
300 CONNELL DRIVE SUITE 4200
-
BERKELEY HEIGHTS,NJ 07922
USA
ph: 908-517-9500
fax: 908-429-4307
daniel@lifesciadvisors.com http://www.cormedix.com
 
 • General Corporate Information   
Officers
Matthew David - Interim Chief Executive Officer and Chief Financia
Myron Kaplan - Director and Chairman of the Board
Paulo Costa - Director
Janet Dillione - Director
Gregory Duncan - Director

Peer Information
CorMedix Inc (CORR.)
CorMedix Inc (RSPI)
CorMedix Inc (CGXP)
CorMedix Inc (BGEN)
CorMedix Inc (GTBP)
CorMedix Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 21900C308
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 39.12
Most Recent Split Date: 3.00 (0.20:1)
Beta: 2.39
Market Capitalization: $127.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.17 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.12
Price/Cash Flow: -
Price / Sales: 1,163.02
EPS Growth
vs. Year Ago Period: 10.00%
vs. Previous Quarter: 10.00%
Sales Growth
vs. Year Ago Period: -90.91%
vs. Previous Quarter: -85.71%
ROE
03/31/22 - -41.69
12/31/21 - -39.01
09/30/21 - -39.16
ROA
03/31/22 - -38.64
12/31/21 - -36.47
09/30/21 - -36.59
Current Ratio
03/31/22 - 14.56
12/31/21 - 12.44
09/30/21 - 14.01
Quick Ratio
03/31/22 - 14.56
12/31/21 - 12.44
09/30/21 - 14.00
Operating Margin
03/31/22 - -25,479.09
12/31/21 - -14,848.95
09/30/21 - -13,952.10
Net Margin
03/31/22 - -25,479.09
12/31/21 - -14,848.95
09/30/21 - -13,952.10
Pre-Tax Margin
03/31/22 - -26,615.45
12/31/21 - -15,429.25
09/30/21 - -14,607.89
Book Value
03/31/22 - 1.55
12/31/21 - 1.65
09/30/21 - 1.82
Inventory Turnover
03/31/22 - 2.80
12/31/21 - 2.84
09/30/21 - 1.81
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©